NO20090145L - Farmasoytiske formuleringer og preparater av en selektiv antagonist mot enten CXCR2 eller bade CXCR1 og CXCR2, og fremgangsmater for anvendelse derav til behandling av inflammatoriske forstyrrelser - Google Patents

Farmasoytiske formuleringer og preparater av en selektiv antagonist mot enten CXCR2 eller bade CXCR1 og CXCR2, og fremgangsmater for anvendelse derav til behandling av inflammatoriske forstyrrelser

Info

Publication number
NO20090145L
NO20090145L NO20090145A NO20090145A NO20090145L NO 20090145 L NO20090145 L NO 20090145L NO 20090145 A NO20090145 A NO 20090145A NO 20090145 A NO20090145 A NO 20090145A NO 20090145 L NO20090145 L NO 20090145L
Authority
NO
Norway
Prior art keywords
cxcr2
treatment
inflammatory disorders
cxcr1
preparations
Prior art date
Application number
NO20090145A
Other languages
English (en)
Norwegian (no)
Inventor
Jim H Kou
Jonathan D Eichman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20090145L publication Critical patent/NO20090145L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20090145A 2006-06-12 2009-01-09 Farmasoytiske formuleringer og preparater av en selektiv antagonist mot enten CXCR2 eller bade CXCR1 og CXCR2, og fremgangsmater for anvendelse derav til behandling av inflammatoriske forstyrrelser NO20090145L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81272406P 2006-06-12 2006-06-12
PCT/US2007/013805 WO2007146296A1 (en) 2006-06-12 2007-06-12 Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders

Publications (1)

Publication Number Publication Date
NO20090145L true NO20090145L (no) 2009-03-11

Family

ID=38626405

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090145A NO20090145L (no) 2006-06-12 2009-01-09 Farmasoytiske formuleringer og preparater av en selektiv antagonist mot enten CXCR2 eller bade CXCR1 og CXCR2, og fremgangsmater for anvendelse derav til behandling av inflammatoriske forstyrrelser

Country Status (18)

Country Link
US (1) US8183287B2 (pt)
EP (1) EP2026770A1 (pt)
JP (1) JP2009539990A (pt)
KR (1) KR20090024248A (pt)
CN (1) CN101500544B (pt)
AR (1) AR061448A1 (pt)
AU (1) AU2007258325B2 (pt)
BR (1) BRPI0713647A2 (pt)
CA (1) CA2654990A1 (pt)
CL (1) CL2007001714A1 (pt)
CO (1) CO6180501A2 (pt)
MX (1) MX2008016016A (pt)
NO (1) NO20090145L (pt)
NZ (1) NZ573566A (pt)
PE (1) PE20080368A1 (pt)
TW (1) TWI351399B (pt)
WO (1) WO2007146296A1 (pt)
ZA (1) ZA200810760B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
JP6702883B2 (ja) * 2014-04-25 2020-06-03 ノーレックス インコーポレイテッド 向神経活性ペプチドの安定な組成物
WO2022155507A1 (en) * 2021-01-15 2022-07-21 Jubilant Pharma Holdings Inc. Transmucosal dosage forms of brexanolone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CN1289471C (zh) 2001-04-16 2006-12-13 先灵公司 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EA200301223A1 (ru) * 2001-05-18 2004-08-26 Рэнбакси Лабораториз Лимитед Лекарственные формы окскарбазепина
WO2003039472A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
EP1469846A2 (en) * 2002-01-07 2004-10-27 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
WO2003080053A1 (en) * 2002-03-18 2003-10-02 Schering Corporation Combination treatments for chemokine-mediated diseases
DE602004025458D1 (de) 2003-04-18 2010-03-25 Schering Corp SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
RU2388756C2 (ru) 2004-01-30 2010-05-10 Шеринг Корпорейшн Кристаллические полиморфные формы лиганда схс-хемокинового рецептора

Also Published As

Publication number Publication date
CL2007001714A1 (es) 2008-01-18
AR061448A1 (es) 2008-08-27
US8183287B2 (en) 2012-05-22
US20080021100A1 (en) 2008-01-24
TWI351399B (en) 2011-11-01
AU2007258325B2 (en) 2013-02-21
JP2009539990A (ja) 2009-11-19
ZA200810760B (en) 2013-05-29
BRPI0713647A2 (pt) 2012-10-23
CO6180501A2 (es) 2010-07-19
CA2654990A1 (en) 2007-12-21
TW200811123A (en) 2008-03-01
WO2007146296A1 (en) 2007-12-21
KR20090024248A (ko) 2009-03-06
MX2008016016A (es) 2009-02-25
NZ573566A (en) 2012-01-12
PE20080368A1 (es) 2008-05-16
CN101500544A (zh) 2009-08-05
EP2026770A1 (en) 2009-02-25
AU2007258325A1 (en) 2007-12-21
CN101500544B (zh) 2012-08-08

Similar Documents

Publication Publication Date Title
DK2046820T3 (da) Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20092652L (no) Konstruert anti-TSLP-antistoff
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
NO20090596L (no) Antivirale fosfinatforbindelser
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
AU2007257423A8 (en) Purine analogs
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
NO20075068L (no) Lipocalinprotein
NO20064584L (no) Tetrahydropyridoindolderivater
CY1114690T1 (el) Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων
MX384206B (es) Formulaciones de inhibidores de dpp iv
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
DK1830881T3 (da) Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2006004684A8 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20082791L (no) 6-fenyl-1H-imidazo[4,5-C]-pyridin-4-karbonitrilderivater som Cathepsin K- og S-inhibitorer
NO20054371L (no) Somatostatin-dopamin kimaere analoger

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application